NYSE:PFEPfizer Stock Price, Forecast & News

Pfizer's stock was trading at $32.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PFE shares have increased by 5.7% and is now trading at $34.0150. View which stocks have been mosted impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Pfizer.

Pfizer is scheduled to release its next quarterly earnings announcement on Tuesday, April 28th 2020. View our earnings forecast for Pfizer.

Pfizer will be holding an earnings conference call on Tuesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Pfizer Inc. (NYSE:PFE) announced its quarterly earnings results on Tuesday, January, 28th. The biopharmaceutical company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by $0.02. The biopharmaceutical company had revenue of $12.69 billion for the quarter, compared to analysts' expectations of $12.73 billion. Pfizer had a net margin of 31.44% and a return on equity of 27.01%. The business's quarterly revenue was down 9.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.64 earnings per share. View Pfizer's earnings history.

Pfizer announced a quarterly dividend on Monday, December 16th. Investors of record on Friday, January 31st will be paid a dividend of $0.38 per share on Friday, March 6th. This represents a $1.52 dividend on an annualized basis and a yield of 4.47%. The ex-dividend date is Thursday, January 30th. This is an increase from Pfizer's previous quarterly dividend of $0.36. View Pfizer's dividend history.

Pfizer declared that its Board of Directors has authorized a share repurchase plan on Friday, December 14th 2018, which permits the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 3.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board believes its stock is undervalued.

Pfizer updated its FY20 earnings guidance on Tuesday, January, 28th. The company provided EPS guidance of $2.82-$2.92 for the period, compared to the Thomson Reuters consensus estimate of $2.72. The company issued revenue guidance of $48.5-$50.5 billion, compared to the consensus revenue estimate of $47.44 billion.

12 equities research analysts have issued 1-year target prices for Pfizer's shares. Their forecasts range from $36.00 to $53.00. On average, they expect Pfizer's stock price to reach $41.30 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price. View analysts' price targets for Pfizer.

Media stories about PFE stock have trended very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pfizer earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutPfizer.

Pfizer saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 59,077,400 shares, an increase of 10.1% from the February 27th total of 53,670,000 shares. Based on an average daily trading volume, of 25,250,000 shares, the short-interest ratio is presently 2.3 days. Approximately 1.1% of the company's stock are short sold. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Pacira Biosciences (PCRX) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), General Electric (GE), Bank of America (BAC), AbbVie (ABBV), Walt Disney (DIS) and Exxon Mobil (XOM).

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer's stock is owned by a number of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.02%), Nexus Investment Management Inc. (0.01%), Park National Corp OH (0.01%), Private Asset Management Inc. (0.01%), Callahan Advisors LLC (0.01%) and Cullinan Associates Inc. (0.00%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View institutional ownership trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including M&R Capital Management Inc., Private Trust Co. NA, Neville Rodie & Shaw Inc., Boltwood Capital Management, Radnor Capital Management LLC, Enterprise Bank & Trust Co, Burns J W & Co. Inc. NY, and Stillwater Investment Management LLC. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, and Frank A Damelio. View insider buying and selling activity for Pfizer.

PFE stock was acquired by a variety of institutional investors in the last quarter, including American National Bank, State of Alaska Department of Revenue, Nexus Investment Management Inc., Park National Corp OH, IMS Capital Management, Xcel Wealth Management LLC, Sound Income Strategies LLC, and CLARET ASSET MANAGEMENT Corp. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc, and Scott Gottlieb. View insider buying and selling activity for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $34.02.

Pfizer has a market capitalization of $188.70 billion and generates $51.75 billion in revenue each year. The biopharmaceutical company earns $16.27 billion in net income (profit) each year or $2.95 on an earnings per share basis. Pfizer employs 88,300 workers across the globe. View additional information about Pfizer.

The official website for Pfizer is http://www.pfizer.com/.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.